Adallen Pharma Limited Sustainability Profile
Adallen Pharma Limited, headquartered in Great Britain, is a prominent player in the pharmaceutical industry, specialising in the development and distribution of innovative healthcare solutions. Founded in 2015, the company has rapidly established itself in key operational regions across Europe and beyond, focusing on advanced drug formulations and delivery systems. With a commitment to quality and efficacy, Adallen Pharma offers a range of core products, including prescription medications and over-the-counter solutions that address various health conditions. Their unique approach to research and development has led to several notable achievements, positioning them as a trusted name in the market. As they continue to expand their portfolio, Adallen Pharma remains dedicated to improving patient outcomes through cutting-edge pharmaceutical advancements.
DitchCarbon Score
How does Adallen Pharma Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Adallen Pharma Limited's score of 26 is lower than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Adallen Pharma Limited's reported carbon emissions
In 2023, Adallen Pharma Limited reported total carbon emissions of approximately 54,000 kg CO2e. The breakdown of these emissions reveals that Scope 1 emissions accounted for about 600 kg CO2e, primarily from mobile combustion. Scope 2 emissions, which include purchased electricity, totalled approximately 5,000 kg CO2e, with 2,690 kg CO2e coming specifically from purchased electricity. The majority of emissions, about 49,000 kg CO2e, fell under Scope 3, which encompasses indirect emissions. Key contributors to Scope 3 emissions included purchased goods and services (20,000 kg CO2e), upstream transportation and distribution (11,000 kg CO2e), and downstream transportation and distribution (14,000 kg CO2e). Currently, Adallen Pharma Limited has not set specific reduction targets or initiatives, nor do they have any climate pledges in place. The absence of formal commitments suggests a need for further development in their climate strategy. As of now, there is no data cascaded from a parent or related organization, indicating that the emissions data is solely from Adallen Pharma Limited itself.
How Carbon Intensive is Adallen Pharma Limited's Industry?
How Carbon Intensive is Adallen Pharma Limited's Location?
Adallen Pharma Limited's Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 41% of Scope 3 emissions.
Top Scope 3 Categories
Adallen Pharma Limited's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Adallen Pharma Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
